Pharma Mar (PHM.MC) Osake Kurssi
Pharma Mar Kurssi
Liikevaihto on kasvanut 5,8 % vuodessa viimeisten 19 vuoden aikana 221,39 M EUR:een. Osakekohtainen tulos on kasvanut 21,2 % vuodessa viimeisten 13 vuoden aikana. Pharma Marn nettomarginaali on nyt 33,9 %, laskenut 40,4 %:sta muutama vuosi sitten. Pharma Marn osinkotuotto on tällä hetkellä noin 1,17 %. Jakosuhde on noin 18 % tuloksesta. Osinko on kasvanut 15,5 % vuodessa viimeisten 18 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 107,10 EUR, eli yli nykyhintaa 56,1 %. 13 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
Pharma Mar osakekurssi
Pharma Mar liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pharma Mar -osakkeesta
The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.
Pharma Mar SA is primarily active in the pharmaceutical industry.
The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.
Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.
Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.
Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.
Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.
Analyytikot asettavat tällä hetkellä Pharma Mar-osakkeelle keskimääräisen tavoitehinnan 99,84 EUR (mediaani: 107,10 EUR), mikä merkitsee +45,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä Pharma Mar-osaketta: 9 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Pharma Mar-yhtiöltä 212,28 M EUR liikevaihtoa ja 1,84 EUR osakekohtaista tulosta.
Pharma Mar-osake (PHM.MC) on listattuna 7 pörssissä, muun muassa: London (0RC6.L), Frankfurt (PMRA.F), München (PMRA.MU), Düsseldorf (PMRA.DU), Madrid (PHM.MC).
Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.
odotettu liikevaihto Pharma Mar on 212,28 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Pharma Mar on 31,72 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Pharma Mar:n hinta-voitto-suhde (P/E) on tällä hetkellä 37,22. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pharma Mar-osakkeen arvostusta.
Pharma Mar:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,56. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pharma Mar-osakkeen arvostuskennuslukuna.
Pharma Mar:n Eulpool-laatuscore on 3/10.
Pharma Mar:n ISIN on ES0169501022. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pharma Mar:n WKN on A2P9YT. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pharma Mar:n ticker on PHM.MC. Tämä pörssinoteeraus käytetään Pharma Mar-osakkeiden kauppaan pörssissä.
Pharma Mar osake
Pharma Mar vertaisryhmä
Pharma Mar Ticker
Pharma Mar FIGI
Kaikki tunnusluvut ja syvällinen analyysi Pharma Mar:sta
Meidän osakeanalyysimme Pharma Mar-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pharma Mar:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: